172 related articles for article (PubMed ID: 16957155)
1. Dasatinib in chronic myelogenous leukemia.
Kathula SK
N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
[No Abstract] [Full Text] [Related]
2. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
3. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
4. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
5. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
6. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-induced pleural effusions: a lymphatic network disorder?
Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
Yun S; Anwer F; Vincelette ND
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
[No Abstract] [Full Text] [Related]
10. Double-edged sword of the new cancer therapeutics.
Force T
Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
[No Abstract] [Full Text] [Related]
11. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; Goldman JM; Apperley JF; Marin D
Br J Haematol; 2008 May; 141(5):745-7. PubMed ID: 18331365
[No Abstract] [Full Text] [Related]
12. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Chen J; Zheng Z; Shen J; Zhou Y
Leuk Lymphoma; 2010 May; 51(5):941-3. PubMed ID: 20350280
[No Abstract] [Full Text] [Related]
13. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
[No Abstract] [Full Text] [Related]
14. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
15. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
[TBL] [Abstract][Full Text] [Related]
16. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G
Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676
[No Abstract] [Full Text] [Related]
17. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
